Selective ghrelin receptor agonist (GHRP) with minimal cortisol / prolactin release.
Ipamorelin is a pentapeptide GHRP that selectively activates the GHS-R1a (ghrelin) receptor, releasing growth hormone with minimal impact on ACTH, cortisol, or prolactin.
Ipamorelin is a pentapeptide growth-hormone-releasing peptide (GHRP) that selectively activates the ghrelin receptor (GHS-R1a) on pituitary somatotrophs. Its defining feature is selectivity: it releases GH with minimal effect on ACTH, cortisol, or prolactin compared with earlier GHRPs.
Because of that clean profile, it is one of the most studied GHRPs in the research literature and is frequently paired with a GHRH analog such as CJC-1295. It is not FDA-approved.
Selective GHS-R1a agonism.
Behind every vial of Ipamorelin is the same exacting pipeline every research peptide runs — but the chemistry plays out differently for this molecule. Here is how Ipamorelin, specifically, is brought into being.
On paper, Ipamorelin is C38H49N9O5 — about 711.9 daltons of precisely arranged atoms. Before a single bond is made, the target sequence, salt form, and purity threshold are written down as the contract the finished material must meet.
Ipamorelin's chain is short but unusual — it carries D-amino acids and non-natural residues that help it resist enzymatic breakdown, but demand specialized, costlier building blocks and careful coupling on the synthesizer. Its C-terminus is amidated rather than left as a free acid — a defined modification the synthesis has to deliver, not an afterthought.
The crude mixture — Ipamorelin plus its deletions and side products — is then separated on preparative HPLC, and where the cut is taken decides the difference between a genuinely pure peptide and a barely-passable one.
A real batch of Ipamorelin proves itself: identity confirmed by mass spectrometry against its ~711.9 Da, purity read directly off an analytical HPLC trace, water and counterion content measured. That batch-specific certificate of analysis is the only honest way to know what is actually in a vial of Ipamorelin — and a short, cold, accountable chain of custody is how that purity survives the trip to your bench.
Producing Ipamorelin to a genuine purity spec means solid-phase synthesis, preparative HPLC purification, and batch quality control — none of it cheap, and none of it something you can verify by eye.
Don't judge a vial by its cake. A fluffy, good-looking lyophilized powder reflects bulking agents and freeze-drying parameters — not purity. Insist on a batch-specific certificate of analysis.
Recent clinical trials and publications mentioning Ipamorelin, pulled automatically from ClinicalTrials.gov and PubMed and refreshed daily. Listings are unfiltered search results, not curated endorsements.
Ipamorelin is a selective ghrelin-receptor agonist (a GHRP) studied for growth-hormone release with minimal effect on cortisol or prolactin.
Its selectivity — releasing GH without significantly raising ACTH, cortisol, or prolactin — distinguishes it from earlier, less selective GHRPs.
GHRPs and GHRH analogs act on separate receptors; combining them is studied for synergistic GH release.
No — it is a research compound. This page is a research and educational reference.
Recombinant 191-amino-acid human growth hormone — a folded protein biologic identical in sequence to pituitary GH, not a synthetic research peptide.
ViewThe downstream effector of growth hormone — a 70-amino-acid recombinant protein, structurally a cousin of proinsulin, that carries out most of GH’s growth signal.
ViewA long-acting modified IGF-1 analog with reduced IGFBP binding and prolonged systemic activity.
ViewDosing protocols, mechanism, comparisons, and the latest trials — citation-backed answers grounded in PubMed, PubChem, and ClinicalTrials.gov.